A phase 1 safety and bioimaging trial of antibody DS-8895a against EphA2 in patients with advanced or metastatic EphA2 positive cancers

Imaging metastatic castration-resistant prostate cancer patients with 89Zr-DFO-MSTP2109A anti-STEAP1 antibody

(2019) Jorge A. Carrasquillo et al.   JOURNAL OF NUCLEAR MEDICINE

Interobserver reproducibility of tumor uptake quantification with 89Zr-immuno-PET: a multicenter analysis

(2019) Yvonne W. S. Jauw et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Safety, tolerability, pharmacokinetics, and pharmacodynamics of the afucosylated, humanized anti-EPHA2 antibody DS-8895a: a first-in-human phase I dose escalation and dose expansion study in patients with advanced solid tumors

(2019) Kohei Shitara et al.   Journal for ImmunoTherapy of Cancer

Novel anti-EPHA2 antibody, DS-8895a for cancer treatment

(2016) Jun Hasegawa et al.   CANCER BIOLOGY & THERAPY

Molecular Imaging and Quantitation of EphA2 Expression in Xenograft Models with 89Zr-DS-8895a

(2016) I. J. G. Burvenich et al.   JOURNAL OF NUCLEAR MEDICINE

Phase I Imaging and Pharmacodynamic Trial of CS-1008 in Patients With Metastatic Colorectal Cancer

(2015) Marika Ciprotti et al.   JOURNAL OF CLINICAL ONCOLOGY

Antibody Positron Emission Tomography Imaging in Anticancer Drug Development

(2015) Laetitia E. Lamberts et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeted Chemoradiation in Metastatic Colorectal Cancer: A Phase I Trial of 131I-huA33 with Concurrent Capecitabine

(2014) R. A. Herbertson et al.   JOURNAL OF NUCLEAR MEDICINE

Phase I Biodistribution and Pharmacokinetic Study of Lewis Y-Targeting Immunoconjugate CMD-193 in Patients with Advanced Epithelial Cancers

(2009) R. A. Herbertson et al.   CLINICAL CANCER RESEARCH

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER